NCT05886881

Brief Summary

The purpose of this Post-Market Clinical Follow-Up (PMCF) study is to assess long term performance and safety of Air Optix Aqua Sphere, Air Optix plus HydraGlyde Sphere, and Air Optix plus HydraGlyde Toric soft contact lenses in a real-world setting when worn as extended (overnight) wear.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
505

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Aug 2023

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

June 2, 2023

Completed
2 months until next milestone

Study Start

First participant enrolled

August 3, 2023

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 15, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2025

Completed
Last Updated

August 14, 2025

Status Verified

August 1, 2025

Enrollment Period

1.7 years

First QC Date

May 24, 2023

Last Update Submit

August 12, 2025

Conditions

Keywords

Contact Lenses

Outcome Measures

Primary Outcomes (4)

  • Distance visual acuity (VA) with study lenses at Year 1

    The subject's chart will be reviewed for distance visual acuity at Year 1, defined as a visit which occurred 1 year (-2/+4 months) since baseline during which period the subject was wearing either the study or comparator lenses and a contact lens examination was performed. The Baseline visit is defined as the first office visit where an eye care practitioner provided an in-person office biomicroscopy exam to the patient before or during which a contact lens prescription for the study or comparator contact lens (lotrafilcon B or comfilcon A) was released.

    Year 1

  • Distance visual acuity (VA) with study lenses at Year 3

    The subject's chart will be reviewed for distance visual acuity at Year 3, defined as a visit which occurred 3 years (-2/+8 months) since baseline during which period the subject was wearing the protocol required contact lenses and a contact lens examination was performed.

    Year 3

  • Incidence of corneal infiltrative events

    The subject's chart will be reviewed for incidences of corneal infiltrative events occurring after the baseline exam.

    Up to Year 3

  • Incidence of microbial keratitis

    The subject's chart will be reviewed for incidences of microbial keratitis occurring after the baseline exam.

    Up to Year 3

Study Arms (5)

Air Optix Aqua Sphere

Lotrafilcon B spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

Device: Lotrafilcon B spherical soft contact lenses

Air Optix plus HydraGlyde Sphere

Lotrafilcon B multifocal soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

Device: Lotrafilcon B spherical soft contact lenses with comfort additive

Air Optix plus HydraGlyde Toric

Lotrafilcon B toric soft contact lenses with comfort additive worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

Device: Lotrafilcon B toric soft contact lenses with comfort additive

Biofinity Sphere

Comfilcon A spherical soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

Device: Comfilcon A spherical soft contact lenses

Biofinity Toric

Comfilcon A toric soft contact lenses worn in both eyes on an extended wear basis. Extended wear is defined as up to 6 days continuous wear (including while sleeping/overnight).

Device: Comfilcon A toric soft contact lenses

Interventions

Commercially available silicone hydrogel contact lenses

Also known as: Air Optix® Aqua Sphere
Air Optix Aqua Sphere

Commercially available silicone hydrogel contact lenses

Also known as: Air Optix® plus HydraGlyde® Sphere
Air Optix plus HydraGlyde Sphere

Commercially available silicone hydrogel contact lenses

Also known as: Air Optix® plus HydraGlyde® Toric
Air Optix plus HydraGlyde Toric

Commercially available silicone hydrogel contact lenses

Also known as: Biofinity Sphere
Biofinity Sphere

Commercially available silicone hydrogel contact lenses

Also known as: Biofinity Toric
Biofinity Toric

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Investigators will enroll charts following a pre-identified process.

You may qualify if:

  • Manifest refraction cylinder less than or equal to 0.75 diopter (D) in each eye at baseline (sphere wearers only);
  • Best corrected visual acuity (BCVA) of 20/25 Snellen or better in each eye at baseline;
  • Must have worn or be wearing Air Optix Aqua Sphere, Air Optix plus HydraGlyde Sphere, Air Optix plus HydraGlyde Toric, Biofinity Sphere or Biofinity Toric for at least 3 years in an extended wear modality, as determined by the Investigator;

You may not qualify if:

  • Any recurrent history or active anterior segment infection, inflammation or abnormality contraindicating regular contact lens wear at baseline;
  • Use of systemic or ocular medications contraindicating regular contact lens wear at baseline and/or during the period of the retrospective chart collection;
  • Slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Vision Health Institute

Orlando, Florida, 32803, United States

Location

Complete Eye Care of Medina

Medina, Minnesota, 55340, United States

Location

Koetting Associates

St Louis, Missouri, 63144, United States

Location

Smith Bowman Ophthalmology

Salt Lake City, Utah, 84117, United States

Location

MeSH Terms

Conditions

Refractive Errors

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

  • Clinical Trial Lead, Vision Care

    Alcon Research, LLC

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2023

First Posted

June 2, 2023

Study Start

August 3, 2023

Primary Completion

April 15, 2025

Study Completion

April 15, 2025

Last Updated

August 14, 2025

Record last verified: 2025-08

Data Sharing

IPD Sharing
Will not share

Locations